Filing Analysis
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the period ending June 30, 2026.
- A press release containing the financial results was issued on August 13, 2026.
Cadrenal Therapeutics announced a strategic realignment of its clinical portfolio into a 'Cardiac Acute Critical Care Franchise.' The company is initiating a structured process to seek out-licensing, monetization, or co-development partnerships for its late-stage assets.
🚩 Red Flags
- The search for 'portfolio monetization' and 'out-licensing' often indicates a need for immediate cash infusion or an attempt to reduce burn rate by offloading asset control.
📋 Key Facts
- Announced the creation of a Cardiac Acute Critical Care Franchise on July 21, 2026.
- Initiated a structured process to secure strategic out-licensing agreements.
- Seeking portfolio monetization opportunities for late-stage assets.
- Exploring commercial co-development partnerships.
Cadrenal Therapeutics, Inc. announced a confidential separation agreement with its Chief Medical Officer, James J. Ferguson III, following his decision to resign. His departure is effective July 31, 2026, and the company is currently searching for a replacement.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in the biotech/life sciences sector can impact clinical development timelines or regulatory strategy.
📋 Key Facts
- James J. Ferguson III resigned as Chief Medical Officer effective July 31, 2026.
- The separation agreement includes salary through the separation date and 100% COBRA premium coverage for six months post-departure (subject to certain conditions).
- The agreement contains a general release of claims and a non-disparagement clause.
- The company is actively conducting a search for a new Chief Medical Officer.
Cadrenal Therapeutics, Inc. announced the resignation of its Chief Medical Officer, James J. Ferguson III, effective July 31, 2026. The company is currently searching for a replacement and is negotiating separation terms.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage/biotech context can disrupt regulatory or clinical development timelines.
📋 Key Facts
- James J. Ferguson III resigned as Chief Medical Officer on July 7, 2026.
- The resignation becomes effective on the Separation Date of July 31, 2026.
- The company is actively conducting a search for a new CMO.
- Negotiations are underway regarding a separation agreement and release.
Cadrenal Therapeutics entered into a private placement agreement with an institutional investor to issue pre-funded warrants and two series of common warrants for approximately $3.0 million in gross proceeds. The financing includes significant dilution potential through various warrant types and carries liquidated damages provisions if registration rights are not met.
🚩 Red Flags
- Significant potential dilution: Total warrant shares (2.88 million) significantly exceed the current gross proceeds scale.
- Liquidated damages clause: The company faces financial penalties if it fails to register securities for resale within 15-45 days.
- At-the-market facility restriction: The company is prohibited from entering a Variable Rate Transaction for one year and cannot use an ATM facility with Wainwright for 60 days post-effective date.
📋 Key Facts
- Gross proceeds from the private placement: approximately $3.0 million.
- Securities issued: Pre-Funded Warrants (up to 960,000 shares), Series C-1 Warrants (up to 960,000 shares), and Series C-2 Warrants (up to 960,000 shares).
- Pre-Funded Warrant exercise price: $0.0001 per share.
- Common Warrants (Series C-1 and C-2) exercise price: $3.00 per share.
- The company agreed to pay liquidated damages of 1% of the investment amount per 30-day period if registration rights are not satisfied within specified deadlines, capped at 6%.
- Directors and officers entered into 60-day lock-up agreements.
Cadrenal Therapeutics, Inc. announced the appointment of John P. Sharp as Interim CFO via a Master Services Agreement with Lohman & Associates, replacing Quang X. Pham in that capacity. The filing also notes the resignation of Board member Steven Zelenkofske and a realignment of the Board's class structure.
🚩 Red Flags
- Use of fractional/interim CFO services via a third-party agency (Lohman & Associates) rather than a full-time employee.
- Rapid turnover in the Interim CFO role (Quang X. Pham replaced by John P. Sharp within the same reporting period).
📋 Key Facts
- John P. Sharp appointed as Interim CFO effective June 25, 2026.
- Quang X. Pham ceased serving as Interim CFO on June 25, 2026.
- Interim CFO services are provided via Lohman & Associates, Inc. at a rate of $455/hour for up to 24 hours per week.
- Steven Zelenkofske resigned from the Board effective June 30, 2026; stated resignation was not due to disagreement with the company.
- Board realignment: Dr. Glynn Wilson moved from Class I to Class III director and reappointed to Audit, Nominating/Governance, and Compensation committees.
Cadrenal Therapeutics announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms. The company also outlined a 'dual-track' portfolio strategy splitting focus between CAD-1005 (Global Pharma Track) and tecarfarin (Regional & Rare Disease Track).
📋 Key Facts
- Planned submission of RPDD request to the FDA for tecarfarin on June 18, 2026.
- Target indication: pediatric patients with Kawasaki disease who develop coronary artery aneurysms (CAAs) requiring chronic oral anticoagulation.
- Implementation of a 'dual-track' strategy: Global Pharma Track (CAD-1005, a 12-LOX inhibitor) and Regional & Rare Disease Track (tecarfarin).
Cadrenal Therapeutics announced the departure of CFO Matthew K. Szot on May 28, 2026. CEO Quang X. Pham has assumed the roles of interim CFO and interim Principal Accounting Officer while the company searches for a permanent replacement.
🚩 Red Flags
- Significant cash outflow for a micro-cap company: total cash payments to the departing CFO exceed $600,000 ($365,806 severance + $237,903 bonus).
- CEO is now consolidating power by acting as both CEO and CFO/Principal Accounting Officer, reducing internal financial oversight.
📋 Key Facts
- Matthew K. Szot transitioned from CFO role effective May 28, 2026.
- CEO Quang X. Pham appointed as interim CFO and interim Principal Accounting Officer.
- Severance agreement signed June 3, 2026, providing Mr. Szot a gross payment of $365,806.00 in four installments.
- Mr. Szot will receive a fiscal 2026 target cash bonus of $237,903.00 in two installments.
- All outstanding stock options for Mr. Szot were accelerated to vest.
Cadrenal Therapeutics, Inc. reported its financial results for the first fiscal quarter ended March 31, 2026. The results were disclosed via a press release attached as an exhibit to the filing.
📋 Key Facts
- The report was filed on May 7, 2026, covering the quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- The company is classified as an emerging growth company.
- A press release containing the financial details was furnished as Exhibit 99.1.
Cadrenal Therapeutics announced the successful completion of its End-of-Phase 2 meeting with the FDA for its lead candidate CAD-1005. The company received guidance on its Phase 3 pivotal trial design and plans to advance directly to a randomized, blinded, placebo-controlled study with a projected NDA submission in 2029.
🚩 Red Flags
- Long timeline to commercialization, with the projected NDA submission not expected until 2029.
- Micro-cap biotech companies face significant funding risks during multi-year Phase 3 clinical trials.
📋 Key Facts
- Completed End-of-Phase 2 meeting with the FDA for CAD-1005, a 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT).
- FDA provided guidance on protocol design, study population, dosing, and the primary endpoint of new or worsening thrombotic events.
- The planned Phase 3 study will involve approximately 120 patients across up to 50 clinical centers worldwide.
- The company intends to submit a New Drug Application (NDA) in 2029.
- CAD-1005 is described as a first-in-class investigational treatment for HIT.
Cadrenal Therapeutics entered into a warrant inducement agreement to raise approximately $2.5 million by drastically reducing the exercise price of existing warrants from $16.50 to $4.50. To induce the cash exercise of 571,430 existing warrants, the company issued 1,142,860 new warrants (Series B-1 and B-2) at the same $4.50 exercise price, representing significant potential dilution.
🚩 Red Flags
- Severe dilution: The company issued two new warrants for every one warrant exercised (200% coverage).
- Drastic repricing: The exercise price was slashed by approximately 72.7% (from $16.50 to $4.50).
- The use of a warrant inducement strategy often indicates a high level of desperation for immediate cash flow.
- Black-Scholes cash-out rights can be toxic for future M&A or financing activities.
📋 Key Facts
- Existing warrants for 571,430 shares had their exercise price reduced from $16.50 to $4.50.
- The company will receive approximately $2.5 million in gross proceeds from the exercise.
- Inducement includes the issuance of 571,430 Series B-1 warrants (5-year term) and 571,430 Series B-2 warrants (18-month term).
- H.C. Wainwright & Co. served as the placement agent, receiving a 7% cash fee and 37,143 placement agent warrants.
- The company is obligated to file a resale registration statement for the new warrant shares within 30 days.
- The new warrants include a Black-Scholes cash-out provision in the event of a Fundamental Transaction.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 8-K on March 31, 2026, to furnish a press release announcing its financial results for the fiscal year ended December 31, 2025. The filing is a routine disclosure of periodic financial performance.
📋 Key Facts
- The company reported financial results for the fiscal year ended December 31, 2025.
- The press release was issued and the 8-K was filed on March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Cadrenal Therapeutics is identified as an emerging growth company.
Cadrenal Therapeutics announced positive pre-clinical research results for its 12-LOX inhibitor, CAD-1005, demonstrating potential in treating obesity-associated inflammation and Type 2 diabetes.
📋 Key Facts
- CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor.
- Pre-clinical models showed oral administration of CAD-1005 improved glycemic control and reduced pancreatic beta-cell loss.
- The research indicates CAD-1005 reduces inflammatory cells in adipose and pancreatic tissues and lowers pro-inflammatory cytokines.
- CAD-1005 was formerly designated as VLX-1005.
- The findings suggest 12-LOX inhibition could be a therapeutic strategy to improve glucose homeostasis.
Cadrenal Therapeutics announced that its Phase 2 trial of CAD-1005 for heparin-induced thrombocytopenia (HIT) failed to meet its primary endpoint of platelet count recovery rate. While the company reported a lower incidence of thrombotic events in the treatment group compared to placebo, the study was not powered to establish statistical significance for this secondary measure.
🚩 Red Flags
- Failure to meet the primary endpoint in a Phase 2 clinical trial.
- The trial results suggest the previous surrogate endpoint (platelet recovery) was invalid for clinical efficacy.
- Reliance on non-statistically significant secondary endpoint data to justify program viability.
📋 Key Facts
- The Phase 2 trial of CAD-1005 (a 12-LOX inhibitor) failed its primary endpoint of platelet count recovery rate.
- The study concluded in December 2025 following a transfer of program ownership from Veralox Therapeutics to Cadrenal.
- Secondary endpoint data showed thrombotic events in 50% of the CAD-1005 group versus >75% in the placebo group.
- The company noted that platelet count recovery did not appear to be a valid surrogate marker for clinical efficacy in this context.
- The trial was not powered to detect statistical significance for the secondary endpoint of thrombotic event incidence.
Cadrenal Therapeutics, Inc. has filed a prospectus supplement to increase its 'at the market' (ATM) offering program by up to $1,770,028 of common stock. This follows previous sales under the same agreement totaling over $10 million.
🚩 Red Flags
- Continuous dilution: The company has already raised $10M through this program and is seeking more, indicating a recurring need for capital.
- Micro-cap financing pattern: Frequent use of ATM offerings is often characteristic of companies with limited cash runway or negative operating cash flow.
📋 Key Facts
- The company is increasing its ATM offering capacity by an additional $1,770,028 in common stock.
- H.C. Wainwright & Co., LLC serves as the sales agent for the program.
- As of December 23, 2025, the company has already sold an aggregate of $10,005,300 through this ATM agreement.
- Wainwright receives a 3.0% commission on gross sales price.
- The offering is conducted under an existing S-3 registration statement originally filed on March 12, 2024.
Cadrenal Therapeutics, Inc. entered into a securities purchase agreement on December 15, 2025, to conduct a registered direct offering of common stock and a concurrent private placement of warrants. The company expects to raise approximately $2.2 million in gross proceeds.
🚩 Red Flags
- Significant dilution: The issuance of warrants to purchase up to 414,748 shares (double the number of common shares being sold) represents substantial potential future dilution.
- High cost of capital: Total placement agent fees and warrants issued to the agent represent a significant percentage of the total offering value.
📋 Key Facts
- Registered direct offering: 207,374 shares at $10.85 per share.
- Private placement of warrants: Up to 414,748 common warrants with an exercise price of $10.60 per share.
- Expected gross proceeds: Approximately $2.2 million.
- Placement Agent: H.C. Wainwright & Co., LLC (7% cash fee + 1% management fee).
- Warrant terms include a cashless exercise option and a 4.99%-9.99% ownership cap for holders.
Cadrenal Therapeutics, Inc. has entered into an Asset Purchase Agreement to acquire all rights and intellectual property related to the VLX-1005 compound and its derivatives from Veralox Therapeutics Inc. The deal includes a $200,000 upfront cash payment, significant contingent milestone payments up to $15 million, and ongoing royalty obligations.
🚩 Red Flags
- Significant contingent liabilities: Up to $15 million in potential milestone payments and ongoing royalties could impact future cash flows.
- Complex royalty structures including tiered rates for the underlying license agreement (2-3% depending on sales volume).
- Potential termination rights by Licensor if Cadrenal fails to meet specific milestone deadlines.
📋 Key Facts
- Acquisition of assets related to VLX-1005 and the VLX-2000 series compounds from Veralox Therapeutics Inc.
- Upfront cash consideration: $200,000.
- Contingent milestone payments totaling up to $15 million based on clinical/regulatory events (e.g., first patient dosing, regulatory filings).
- Royalty obligations: 5% on Annual Net Sales of products containing the compounds; subject to a 50% reduction in territories with generic competition.
- Assumption of an exclusive license agreement from Old Dominion University regarding EVMS Patent Rights (12-LOX inhibitors).
- Licensee must pay Licensor $300,000 in milestone payments upon regulatory approval in specific regions by 2031/2032.
- Minimum annual royalty to Licensor of $10,000–$50,000 (waived for FY2026-2028; first payment due May 1, 2029).
Cadrenal Therapeutics, Inc. announced the appointment of Lee Scott Golden, M.D., to its Board of Directors as a Class II director and member of the Science and Technology Committee.
📋 Key Facts
- Dr. Lee Scott Golden appointed to serve as a Class II director until the 2027 annual meeting.
- Appointed to the Board's Science and Technology Committee.
- Currently serves as EVP and Chief Medical Officer at PTC Therapeutics, Inc.
- Annual compensation for 2025 is set at $35,000 plus equity awards.
- Dr. Golden has over 25 years of industry experience in clinical development and regulatory activities.
Cadrenal Therapeutics, Inc. has filed a prospectus supplement to increase its 'at the market' (ATM) offering program by up to $3,438,062 of common stock. This follows previous sales under the same agreement totaling approximately $9.39 million.
🚩 Red Flags
- Potential dilution for existing shareholders as new common stock is issued into the market.
- Frequent use of ATM offerings can indicate a need for continuous liquidity to fund operations, often seen in micro-cap biotech/life sciences companies.
📋 Key Facts
- The company is increasing the capacity of its existing ATM offering program by $3,438,062.
- H.C. Wainwright & Co., LLC serves as the sales agent for these offerings.
- As of November 18, 2025, the company has already sold an aggregate of $9,386,964 in common stock via this program.
- Wainwright will receive a 3.0% compensation fee on the gross sales price of all shares sold through the ATM agreement.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the fiscal quarter ended September 30, 2025.
- A press release was issued on November 10, 2025, as Exhibit 99.1.
Cadrenal Therapeutics, Inc. held its 2025 annual meeting of stockholders on September 24, 2025. The meeting resulted in the election of a new director and the ratification of the company's independent auditor.
🚩 Red Flags
- High number of Broker Non-Votes (600,153) for the director election relative to total shares outstanding.
📋 Key Facts
- Held 2025 Annual Meeting of Stockholders on September 24, 2025.
- Steven Zelenkofske was elected as a Class III director to serve until the 2028 annual meeting.
- WithumSmith+Brown, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Quorum was met with 1,284,746 shares present out of 2,046,854 total shares outstanding (approx. 62.7% quorum).
- Proposal 1 received 669,494 votes 'For' and 600,153 'Broker Non-Votes'.
Cadrenal Therapeutics, Inc. has entered into an Asset Purchase Agreement to acquire the rights to eXIthera Pharmaceuticals' compounds Frunexian (EP-7041) and EP-7327, including all associated intellectual property and regulatory filings. The deal includes a $50,000 upfront cash payment, contingent milestones up to $15 million, and ongoing royalty obligations.
🚩 Red Flags
- Significant contingent liabilities: Up to $15 million in milestone payments and ongoing royalty obligations could impact future cash flows.
📋 Key Facts
- Acquisition of assets related to Frunexian (EP-7041) and EP-7327 from eXIthera Pharmaceuticals, Inc.
- Upfront cash payment: $50,000 for transaction closing costs.
- Contingent milestone payments totaling up to $15 million based on clinical/regulatory events (Phase 1, Phase 2, Phase 3 dosing and FDA NDA approval).
- Royalty obligation of 2% of Annual Net Sales in non-China markets until patent expiration or 10 years from first sale.
- Assumption of 50% of royalties received from Haisco under the existing Haisco License Agreement for China.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the fiscal quarter ended June 30, 2025.
- A press release containing the financial results was issued on August 11, 2025.
Cadrenal Therapeutics, Inc. announced clinical trial initiation plans for its lead drug candidate, tecarfarin. The trials target patients with end-stage kidney disease transitioning to dialysis and will include both atrial fibrillation and non-atrial fibrillation patients.
📋 Key Facts
- Lead late-stage drug candidate: tecarfarin
- Target patient population: End-stage kidney disease transitioning to dialysis
- Trial scope: Includes patients with and without atrial fibrillation
- Timeline: Enrollment planned to begin later in 2025
Cadrenal Therapeutics, Inc. announced the immediate resignation of Class II Director Robert Lisicki on July 15, 2025. The company also provided notice regarding the upcoming 2025 Annual Meeting of stockholders and revised deadlines for stockholder proposals.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Robert Lisicki resigned from the Board of Directors effective July 15, 2025.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- The 2025 Annual Meeting of stockholders is scheduled for September 24, 2025.
- The record date for the annual meeting is July 28, 2025.
- Revised deadlines for Rule 14a-8 stockholder proposals and director nominations have been set for July 28, 2025.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the fiscal quarter ended March 31, 2025.
- A press release containing the financial results was issued on May 8, 2025.
Cadrenal Therapeutics, Inc. has filed a prospectus supplement to expand its 'at the market' (ATM) offering program, allowing for the sale of up to 2,169,272 additional shares of common stock through H.C. Wainwright & Co., LLC.
🚩 Red Flags
- Continued reliance on ATM offerings suggests a need for immediate liquidity to fund operations.
- Potential for significant shareholder dilution through the issuance of up to 2.17 million new shares.
📋 Key Facts
- The company is increasing its ATM offering capacity by up to 2,169,272 shares of common stock.
- H.C. Wainwright & Co., LLC serves as the sales agent under an existing agreement dated March 11, 2024.
- As of April 17, 2025, the company has already sold $7,655,240 worth of shares via this ATM program.
- Wainwright is entitled to a 3.0% compensation fee on gross sales prices.
- The offering is conducted under an existing Form S-3 registration statement (File No. 333-277835) declared effective March 20, 2024.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the earnings press release issued on March 13, 2025.
📋 Key Facts
- The company released financial information for the fiscal year ended December 31, 2024.
- The report was filed on March 13, 2025.
- The filing includes a press release as Exhibit 99.1 regarding results of operations and financial condition.
Cadrenal Therapeutics entered into a Collaboration Agreement with Abbott Global Enterprises Limited to conduct a Phase 3 study for tecarfarin in patients with left-ventricular assist devices (LVAD). The agreement involves data sharing from Abbott's existing trials and collaboration on biostatistics, site selection, and recruitment.
🚩 Red Flags
- The company explicitly states it is 'pursuing business development strategies, including licenses and funding partnerships, to support funding the Phase 3 study,' indicating a need for external capital to execute this clinical program.
📋 Key Facts
- Entered into Collaboration Agreement with Abbott Global Enterprises Limited on March 3, 2025.
- The partnership focuses on a Phase 3 study: 'TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices'.
- Abbott will share data from its MOMENTUM 3 and ARIES HM3 US IDE trials to support the Study's protocol and regulatory submissions.
- Cadrenal Therapeutics remains the regulatory sponsor of the study, bearing responsibility for monitoring and regulatory interaction.
- Intellectual property related to tecarfarin resulting from the study will be solely owned by Cadrenal Therapeutics.
Cadrenal Therapeutics, Inc. announced a leadership transition in its medical department, appointing Dr. James J. Ferguson III as Chief Medical Officer and simultaneously announcing the amicable departure of the previous CMO, Douglas Losordo.
🚩 Red Flags
- Rapid turnover in a key executive role (CMO) within the same reporting period.
- Severance obligations for departing officer include accelerated vesting of options.
📋 Key Facts
- Dr. James J. Ferguson III appointed as Chief Medical Officer effective February 5, 2025.
- Dr. Ferguson's compensation includes a $505,000 annual base salary and up to 40% discretionary bonus.
- Dr. Ferguson granted 60,000 stock options with a 25% cliff vesting on March 1, 2026.
- Douglas Losordo terminated from the CMO role on February 4, 2025, via mutual agreement.
- Severance for Dr. Losordo includes 6 months of base salary, 50% of his 2025 target bonus, and COBRA coverage.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial information pertains to the fiscal quarter ended September 30, 2024.
- A press release was issued on November 7, 2024, as Exhibit 99.1.
Cadrenal Therapeutics entered into a warrant inducement agreement to encourage the exercise of existing warrants at a significantly reduced price. In exchange, the company issued new Series A-1 and A-2 warrants to the holder, resulting in approximately $4.7 million in gross proceeds.
🚩 Red Flags
- Significant dilution: The issuance of new warrants (Series A-1 and A-2) at a reduced exercise price creates substantial potential dilution for existing shareholders.
- Warrant Inducement: Reducing the exercise price from $26.25 to $16.50 is a dilutive event used to secure immediate cash flow.
- Cashless Exercise Provision: The new warrants include a cashless exercise option if a registration statement is not effective within 60 days of closing.
📋 Key Facts
- The transaction closed on November 4, 2024.
- Existing warrants were exercised at a reduced price of $16.50 per share (down from $26.25).
- The company received approximately $4.7 million in aggregate gross proceeds before fees.
- New Series A-1 and A-2 warrants were issued to the holder, equal to 100% of the number of shares issued upon exercise.
- H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 7.0% cash fee and 6.5% in placement agent warrants.
- The company expects to use net proceeds for its pivotal Phase 3 trial and partnering activities.
Cadrenal Therapeutics, Inc. announced the sale of 391,243 shares of common stock via its at-the-market (ATM) facility. The transaction generated approximately $5.1 million in gross proceeds at a weighted average price of $13.15 per share.
🚩 Red Flags
- Equity dilution for existing shareholders via ATM offering.
📋 Key Facts
- Sold 391,243 shares of common stock through an ATM facility.
- Weighted average sale price: $13.15 per share.
- Gross proceeds generated: approximately $5.1 million.
- Total shares outstanding as of October 23, 2024: 1,496,771 shares.
Cadrenal Therapeutics, Inc. has released an updated corporate presentation via its website to provide investors with updates on clinical trial plans.
📋 Key Facts
- Updated corporate presentation posted on September 25, 2024.
- Presentation includes Phase 3 trial plans for lead indication: patients with an approved left-ventricular assist device (LVAD).
- Presentation covers two additional indications: end stage kidney disease with atrial fibrillation and mechanical heart valve patients with warfarin resistance/difficult TTR.
Cadrenal Therapeutics, Inc. has regained compliance with Nasdaq's minimum bid price requirement. The company successfully maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
🚩 Red Flags
- Previous non-compliance with minimum bid price requirements (implied by the resolution of the notice).
📋 Key Facts
- The company received a notification from Nasdaq regarding potential delisting due to the stock price falling below $1.00.
- Compliance period: August 20, 2024, through September 4, 2024.
- The Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).
- Nasdaq has declared the delisting matter closed.
Cadrenal Therapeutics, Inc. has implemented a 1-for-15 reverse stock split effective August 20, 2024. The action was taken to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
🚩 Red Flags
- Reverse stock split is a common defensive measure to avoid delisting due to low share price.
- The company explicitly states the split is intended to meet Nasdaq's $1.00 minimum bid price requirement, indicating significant downward pressure on the stock price previously.
📋 Key Facts
- Reverse stock split ratio is 1-for-15.
- Effective date: August 20, 2024, at 12:01 a.m. ET.
- The split reduces outstanding shares from approximately 16 million to approximately 1.1 million.
- No fractional shares will be issued; instead, cash payments based on the 10-day average closing price will be provided.
- New CUSIP number: 127636 207.
Cadrenal Therapeutics, Inc. is implementing a 1-for-15 reverse stock split effective August 20, 2024. The action aims to bring the company into compliance with Nasdaq's $1.00 minimum bid price requirement.
🚩 Red Flags
- Reverse stock split is a common defensive measure to avoid delisting.
- The company is currently non-compliant with Nasdaq's $1.00 minimum bid price requirement.
📋 Key Facts
- Reverse stock split ratio: 1-for-15.
- Effective Date/Time: August 20, 2024, at 12:01 a.m. ET.
- Expected share reduction: From approximately 16 million shares to approximately 1.1 million shares.
- New CUSIP number: 127636 207.
- Fractional shares will be settled in cash based on the 10-day average closing price preceding the effective time.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- The company issued a press release on August 7, 2024, containing financial information for the quarter ending June 30, 2024.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Quang Pham, Chairman and CEO.
Cadrenal Therapeutics announced the initiation of collaborative efforts with Abbott to advance a planned pivotal trial for tecarfarin in patients with recently implanted left ventricular assist devices (LVADs). The announcement was made via press release under Items 7.01 and 8.01.
📋 Key Facts
- Collaborative efforts initiated with Abbott on August 6, 2024.
- The collaboration focuses on a planned pivotal trial for tecarfarin.
- Target patient population: patients with recently implanted left ventricular assist devices (LVADs).
- Information was released via press release furnished as Exhibit 99.1.
Cadrenal Therapeutics, Inc. held its 2024 Annual Meeting of Stockholders where shareholders approved several significant structural changes, including a potential reverse stock split and an increase in authorized shares.
🚩 Red Flags
- Approval of a reverse stock split (ratio 1-for-2 to 1-for-20), often used to maintain Nasdaq listing compliance or attract institutional investors by raising share price.
- Significant increase in authorized shares (from 75M to 125M) which can lead to future dilution.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation allowing the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-20.
- Stockholders approved increasing authorized Common Stock from 75,000,000 to 125,000,000 shares.
- Stockholders approved an amendment to the 2022 Successor Equity Incentive Plan, increasing available shares by 2,000,000 to a total of 4,604,550 shares.
- The 'evergreen provision' was amended to allow annual issuance of up to 20% of outstanding common stock plus issuable warrants/pre-funded warrants.
- Two directors (John Murphy and Robert Lisicki) were elected to serve until the 2027 Annual Meeting.
Cadrenal Therapeutics, Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders for July 29, 2024, and established revised deadlines for stockholder proposals and director nominations.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders is scheduled for July 29, 2024.
- The record date for determining stockholders entitled to vote is the close of business on June 6, 2024.
- Stockholder proposals under Rule 14a-8 must be received by May 20, 2024, to be included in proxy materials.
- Director nominations or other proposals not seeking inclusion in proxy materials must also be delivered by May 20, 2024.
- Stockholders intending to solicit proxies for nominees other than the company's must provide notice by May 30, 2024.
Cadrenal Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation for tecarfarin. This designation is intended for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices.
📋 Key Facts
- FDA granted Orphan Drug Designation for tecarfarin on April 9, 2024.
- Target indication: prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (LVAD, RVAD, biventricular assist device, or total artificial heart).
- The announcement was made via a press release furnished under Item 7.01.
Cadrenal Therapeutics, Inc. entered into an At the Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $5,143,730 in common stock.
🚩 Red Flags
- Potential for immediate share dilution through ATM program.
- The company's ability to sell shares depends on the effectiveness of an S-3 filing, which is not guaranteed.
📋 Key Facts
- Entered into ATM Agreement on March 11, 2024.
- Sales agent: H.C. Wainwright & Co., LLC.
- Maximum offering amount: $5,143,730 in common stock.
- Wainwright compensation: 3.0% of the gross sales price.
- Issuance is subject to the effectiveness of a Form S-3 Registration Statement filed on March 11, 2024.
Cadrenal Therapeutics, Inc. filed an 8-K to announce the issuance of a press release containing financial information for the fiscal year ended December 31, 2023.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial information pertains to the fiscal year ended December 31, 2023.
- A press release was issued on March 11, 2024, as Exhibit 99.1.
Cadrenal Therapeutics received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company must meet a $1.00 per share threshold for at least 10 consecutive business days by September 3, 2024, or face delisting.
🚩 Red Flags
- Delisting notice/non-compliance risk
- Potential for a reverse stock split to artificially boost share price
- Ongoing failure to meet minimum bid price requirements (Rule 5550(a)(2))
📋 Key Facts
- Nasdaq granted a 180-day extension to regain compliance with Listing Rule 5550(a)(2).
- The deadline to demonstrate compliance is September 3, 2024.
- Compliance requires the stock to maintain a minimum bid price of $1.00 for at least 10 consecutive business days.
- Failure to comply by the deadline will result in written notification of delisting from the Nasdaq Capital Market.
Cadrenal Therapeutics, Inc. is reporting an update regarding its non-compliance with Nasdaq's minimum bid price requirement of $1.00 per share. While the company briefly traded above the threshold for 14 consecutive business days in early 2024, it has not yet regained official compliance and is considering a reverse stock split to meet requirements.
🚩 Red Flags
- Delisting risk due to failure to maintain minimum bid price requirement.
- Potential for a reverse stock split to artificially inflate share price.
- Uncertainty regarding official Nasdaq determination of compliance despite recent price action.
📋 Key Facts
- Received Nasdaq notice regarding non-compliance with Rule 5550(a)(2) (minimum $1.00 bid price).
- The initial 180-day compliance period was set to expire on March 4, 2024.
- Stock traded above $1.00 for 14 consecutive business days between Jan 19, 2024, and Feb 7, 2024.
- Nasdaq has not yet officially notified the company that compliance has been regained.
- The company intends to request an additional 180-day extension to regain compliance.
Cadrenal Therapeutics, Inc. announced the appointment of Jeffrey Cole as Chief Operating Officer (COO), effective February 8, 2024. The filing details his employment agreement, including compensation and equity incentives.
🚩 Red Flags
- None identified in this specific filing.
📋 Key Facts
- Jeffrey Cole appointed as Chief Operating Officer (COO) effective February 8, 2024.
- Annual base salary of $405,000 with a discretionary bonus up to 40% of base salary.
- Severance package includes 12 months of base salary and full target cash bonus for the current fiscal year in the event of termination without cause.
- Grant of 150,000 stock options under the 2022 Successor Equity Incentive Plan, vesting over a 4-year period (25% at one year, then pro rata monthly).
- Mr. Cole has been a consultant to the Company since November 2023.